From: www.ecancer.tv on Thu, Jul 22 2010 11:51 AM

Dr Infante discusses the work the Sarah Cannon Research Institute does and the benefits the launch of the UK programme will bring. He discusses the research the institute is presenting at ASCO 2010 and outlines the findings of his research into the MEK 1/2 inhibitor GSK1120212.

From: www.ecancer.tv on Thu, Jul 22 2010 11:51 AM

Prof Jonathan Ledermann outlines some of the key advances in ovarian cancer that have been presented at ASCO 2010. Prof Ledermann discusses research demonstrating the effectiveness of combining bevacizumab with chemotherapy as first line treatment of ovarian cancer. A second key presentation was ...

From: www.ecancer.tv on Thu, Jul 22 2010 6:02 AM

Dr Merlini talks at ASCO about amyloidosis and the importance of its early diagnosis and the symptoms such as protein in urine and cardiology issues. He also discusses the treatments for amyloidosis and future trials.

From: www.ecancer.tv on Tue, Jul 20 2010 3:26 PM

Prof Perrotti speaks about the discovery that microRNA can be used to bind to proteins and block their function. Initial results suggest this could be an effective way of treating myeloid leukaemia. The microRNA miR-328 is added to cells in blast crisis where they block the protein C/EBP alpha, ...

From: www.ecancer.tv on Tue, Jul 20 2010 3:26 PM

Prof Parulekar speaks about the NCIC and the interim results of their study, carried out in partnership with the UK Medical Research Council, into the impact of radiotherapy on patients with high risk localised prostate cancer. The results show that radiotherapy in combination with hormone thera...

From: www.ecancer.tv on Tue, Jul 20 2010 3:26 PM

Prof Burnett speaks about research into the treatment of AML presented at the 2010 EHA congress. The topics include developments with immunoconjugates, clofarabine and the hopes for the FLT3 inhibitor AC220. Prof Burnett discusses how his group decides which drugs should be evaluated in clinical...

From: www.ecancer.tv on Tue, Jul 20 2010 1:58 PM

Prof Schwartz discusses the use of targeted therapy to treat sarcomas. Imatinib has been shown to reduce recurrence rates and has traditionally been administered daily for a year after surgery. Prof Schwartz speaks about wok that has been done that will help clinicians decide which patients need ...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Dr Thomssen discusses the difficulties faced when developing personalised medicine and the importance of prognostic and predictive markers in this process. Dr Thomssen speaks about the importance of the BRCA1 and BRCA2 mutations and how the PARP expression of ER+/ER- tumours can be used as a pred...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Dr Soria speaks about locally advanced non-small cell lung cancer and the importance of personalised therapy. The development of drugs such as crizotinib, which are successful at treating a specific subset of patients, is significantly increasing the effectiveness of lung cancer treatment. Dr di...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Calvert speaks about his current work at UCL developing phase I and translational research in addition to working with the UCL bioscience department to develop novel cancer treatments. Prof Calvert then explains the background to his important work developing PARP inhibitors and outlines how...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Wagstaff speaks about his highlights from the 2010 ASCO conference. These include the extremely positive results of a trial investigating ipilimumab. This monocolonal antibody modulates the immune system, activating a T-cell response which helps the body fight metastatic melanoma. A number ...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Demetri describes two key presentations from ASCO 2010: the rapid progress made developing a therapy for ALK mutation related non-small cell lung cancer patients and the encouraging results of a phase I study into inflammatory myofibroblastic tumour patients with the ALK mutation. Prof Demit...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Dr Briest talks about results from ASCO 2010 that will influence the way breast cancer is treated. These include research into the relationship between obesity and response to treatment, the influence of hormone replacement therapy on breast cancer prognosis and the effect of radiation on elderl...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Eggermont talks about the significance of ipilimumab. This monoclonal antibody, although developed to treat melanoma, could have important implications in the fight against many tumours. Ipilimumab affects tumours by modulates the immune system; activating a T-cell response that had been si...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Zwierzina discusses the Biotherapy Development Association (BDA), a group that brings together pre-clinical and clinical scientists in order to improve links between translational research and clinical trials. The BDA provides a platform for the regulators, industry and academia to discuss ...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Michael Baumann, president of ECCO, discusses an ECCO ASCO joint symposium that will take place at all future ECCO and ASCO conferences. Prof Baumann explains why it is important that ECCO and ASCO work closely together and outlines what was discussed at the latest symposium.

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Aapro speaks about the difficulties of treating cancer in elderly patients. When treating elderly cancer patients clinicians must consider a number of factors such as creatinine clearance, nutritional status and gastric acidity. Although treatments can be very effective in fit elderly cance...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Dr Silvia Marsoni and Prof Filippo de Braud discuss the key research that has stood out from ASCO 2010, including PI3K, ERK, BRAF, MEK and TOR and inhibitors. Dr Marsoni goes on to explain why it was important that the results presented at this years conference were not exclusively from successf...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Kaye talks about the future of ovarian cancer research. One area that is expected to be very important is research targeting the VEGF protein. A key presentation at ASCO 2010 has shown that a maintenance treatment of avastin, a targeted therapy that blocks VEGF, increases overall survival i...

From: www.ecancer.tv on Tue, Jul 20 2010 1:56 PM

Prof Mason speaks about the results of an inter-group trial conducted by the UK Medical Research Council in collaboration with the National Cancer Institute of Canada. This trial looked at men with locally advanced or localised non-metastatic prostate cancer and challenging the results of a previ...